TODENTJ-25-03-2019_TODENTJ-8-109 1553505538 Bentham Open doi@benthamopen.net Bentham Open The Open Dentistry Journal TODENTJ 1874-2106 5 30 2014 8 1 Aruni Tilakaratne Mena Soory The non-antimicrobial properties of tetracyclines such as anti-inflammatory, proanabolic and anti-catabolic actions make them effective pharmaceuticals for the adjunctive management of chronic inflammatory diseases. An over-exuberant inflammatory response to an antigenic trigger in periodontitis and other chronic inflammatory diseases could contribute to an autoimmune element in disease progression. Their adjunctive use in managing periodontitis could have beneficial effects in curbing excessive inflammatory loading from commonly associated comorbidities such as CHD, DM and arthritis. Actions of tetracyclines and their derivatives include interactions with MMPs, tissue inhibitors of MMPs, growth factors and cytokines. They affect the sequence of inflammation with implications on immunomodulation, cell proliferation and angiogenesis; these actions enhance their scope, in treating a range of disease entities. Non-antimicrobial chemically modified tetracyclines (CMTs) sustain their diverse actions in organ systems which include anti-inflammatory, anti-apoptotic, anti-proteolytic actions, inhibition of angiogenesis and tumor metastasis. A spectrum of biological actions in dermatitis, periodontitis, atherosclerosis, diabetes, arthritis, inflammatory bowel disease, malignancy and prevention of bone resorption is particularly relevant to minocycline. Experimental models of ischemia indicate their specific beneficial effects. Parallel molecules with similar functions, improved Zn binding and solubility have been developed for reducing excessive MMP activity. Curbing excessive MMP activity is particularly relevant to periodontitis, and comorbidities addressed here, where specificity is paramount. Unique actions of tetracyclines in a milieu of excessive inflammatory stimuli make them effective therapeutic adjuncts in the management of chronic inflammatory disorders. These beneficial actions of tetracyclines are relevant to the adjunctive management of periodontitis subjects presenting with commonly prevalent comorbidities addressed here. 5 30 2014 109 124 TODENTJ-8-109 1 10.2174/crossmark_policy opendentistryjournal.com benthamopen.com true Peer Reviewed Single blind Checked with iThenticate 2014-2-10 2014-4-8 2014-5-12 2014-5-30 http://creativecommons.org/licenses/by-nc/3.0/ 10.2174/1874210601408010109 1553505538 https://opendentistryjournal.com/VOLUME/8/PAGE/109/ https://opendentistryjournal.com/contents/volumes/V8/TODENTJ-8-109/TODENTJ-8-109.pdf https://opendentistryjournal.com/contents/volumes/V8/TODENTJ-8-109/TODENTJ-8-109.pdf https://opendentistryjournal.com/contents/volumes/V8/TODENTJ-8-109/TODENTJ-8-109.pdf https://opendentistryjournal.com/contents/volumes/V8/TODENTJ-8-109/TODENTJ-8-109.pdf https://opendentistryjournal.com/contents/volumes/V8/TODENTJ-8-109/TODENTJ-8-109.pdf https://opendentistryjournal.com/contents/volumes/V8/TODENTJ-8-109/TODENTJ-8-109.pdf https://opendentistryjournal.com/contents/volumes/V8/TODENTJ-8-109/TODENTJ-8-109.pdf https://opendentistryjournal.com/contents/volumes/V8/TODENTJ-8-109/TODENTJ-8-109.xml Pharmacol Res Golub LM 63 99 2011 Golub LM. Introduction and background. Pharmacol Res 2011; 63 : 99-101. J Periodontal Res Choi DH 39 20 2004 Choi DH, Moon IS, Choi BK. Effects of sub-antimicrobial dose of doxycycline therapy on crevicular fluid MMP-8 and gingival tissue MMP-9. TIMP-1 and IL-6 levels in chronic periodontitis. J Periodontal Res 2004; 39 : 20-6. Pharmacol Res Payne JB 63 121 2011 Payne JB, Golub LM. Using tetracyclines to treat osteoporotic/osteopenic bone loss: from the basic science laboratory to the clinic. Pharmacol Res 2011; 63 : 121-9. J Phys Chem B Marcial BL 116 13644 2012 Marcial BL, Sousa SF, Barbosa IL, Dos Santos HF, Ramos MJ. Chemically modified tetracyclines as inhibitors of MMP-2 matrix metalloproteinase: a molecular and structural study. J Phys Chem B 2012; 116 : 13644-54. Shock Roy SK 37 424 2012 Roy SK, Kubiak BD, Albert SP. Chemically-modified tetracycline-3 prevents acute respiratory distress syndrome in a porcine model of sepsis plus ischemia/reperfusion lung injury. Shock 2012; 37 : 424-32. Br J Pharmacol Garrido-Mesa N 169 337 2013 Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol 2013; 169 : 337-52. Br Dent J Johnston S 215 71 2013 Johnston S. Feeling blue?.Minocycline-induced staining of the teth.oral mucosa., sclerae and ears a case report. Br Dent J 2013; 215 : 71-3. Curr Med Chem Zhang Y 19 4348 2012 Zhang Y, Gu Y, Lee HM. Design. synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins. Curr Med Chem 2012; 19 : 4348-58. Biochem Res Int Devy L 2011 191670 2011 Devy L, Dransfield DT. New strategies for the next generation of matrix-metalloproteinase inhibitors: selectively targeting membrane-anchored MMPs with therapeutic antibodies. Biochem Res Int 2011; 2011 : 191670. Pharmacol Res Garrido-Mesa N 67 18 2013 Garrido-Mesa N, Zarzuelo A, Gálvez J. What is behind the non-antibiotic properties of minocycline?. Pharmacol Res 2013; 67 : 18-30. Pharmacol Res Griffin MO 63 102 2011 Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res 2011; 63 : 102-7. Dermatol Clin Webster G 25 133 2007 Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin 2007; 25 : 133-5. J Neurochem Kraus RL 94 819 2005 Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang a, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem 2005; 94 : 819-27. Inflammopharmacology Leite LM 19 99 2011 Leite LM, Carvalho AGG, Tavares Ferreira PLF. Anti-inflammatory properties of doxycycline and minocycline in experimental models: an in vivo and in vitro comparative study. Inflammopharmacology 2011; 19 : 99-110. Stroke Yenari MA 37 1087 2006 Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG. Microglia potentiate damage to blood-brain barrier con-stituents: improvement by minocycline in vivo and in vitro. Stroke 2006; 37 : 1087-93. Spine Sonmez E 38 1253 2013 Sonmez E, Kabatas S, Ozen O. Minocycline treatment inhibits lipid peroxidation. preserves spinal cord ultrastructure and improves functional outcome after traumatic spinal cord injury in the rat. Spine 2013; 38 : 1253-9. J Periodontol Takashiba S 74 103 2003 Takashiba S, Naruishi K, Murayama Y. Perspective of cytokine regulation for periodontal treatment: fibroblast biology. J Periodontol 2003; 74 : 103-. Recent Pat Endocr Metab Immune Drug Discov El-Shinnawi U 7 169 2013 El-Shinnawi U, Soory M. Associations between periodontitis and systemic inflammatory diseases: response to treatment. Recent Pat Endocr Metab Immune Drug Discov 2013; 7 : 169-88. Pharmacol Res Caton J 63 114 2011 Caton J, Ryan ME. Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD). Pharmacol Res 2011; 63 : 114-20. J Periodontol Serhan CN 79 1520 2008 Serhan CN. Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators. J Periodontol 2008; 79 : 1520-6. J Oral Microbiol. Gu Y 4 2012 Gu Y, Walker C, Ryan ME, Payne JB, Golub LM. Non-antibacterial tetracycline formulations clinical applications in dentistry and medicine.Epub 2012 Oct 12 J Oral Microbiol 2012; 4 ISRN Dent Moreno Villagrana AP 2012 581207 2012 Moreno Villagrana AP, Gomez Clavel JF. Antimicrobial or sub antimicrobial antibiotic therapy as an adjunct to the nonsurgical periodontal treatment: a meta-analysis. ISRN Dent 2012; 2012 : 581207- 11. Arch Oral Biol Gomes PS 52 251 2007 Gomes PS, Fernandes MH. Effect of therapeutic levels of doxycycline and minocycline in the proliferation and differentiation of human bone marrow osteoblastic cells. Arch Oral Biol 2007; 52 : 251-9. Periodontol 2000 Kirkwood KL 43 294 2007 Kirkwood KL, Cirelli JA, Rogers JE, Giannobile WV. Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 2007; 43 : 294-315. J Clin Pharmacol Basegmez C 51 915 2011 Basegmez C, Berber L, Yalcin F. Clinical and biochemical efficacy of minocycline in non-surgical periodontal therapy: a randomized controlled pilot study. J Clin Pharmacol 2011; 51 : 915-22. J Pharm Bioallied Sci Honibald EN 4 S417 2012 Honibald EN, Mathew S, Padmanaban J, Sundaram E, Ramamoorthy RD. Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory perio-dontal disease. J Pharm Bioallied Sci 2012; 4 (Suppl 2 ) : S417-21. J Periodontol Giannobile WV 79 1592 2008 Giannobile WV. Host-response therapeutics for periodontal diseases. J Periodontol 2008; 79 : 1592-600. Ann NY Acad Sci Ashley RA 878 335 1999 Ashley RA. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease.SDD Clinical Research Team. Ann NY Acad Sci 1999; 878 : 335-46. Ann Med Sorsa T 38 306 2006 Sorsa T, Tjäderhane L, Konttinen YT. Matrix metalloproteinases: contribution to pathogenesis.diagnosis and treatment of periodontal inflammation. Ann Med 2006; 38 : 306-21. Adv Dent Res Ciancio S 12 27 1998 Ciancio S, Ashley R. Safety and efficacy of subantimicrobial-dose doxycycline therapy in patients with adult periodontitis. Adv Dent Res 1998; 12 : 27-31. J Periodontol Caton JG 71 521 2000 Caton JG, Ciancio SG, Blieden TM. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol 2000; 71 : 521-32. Indian J Pharmacol Agnihotri R 44 161 2012 Agnihotri R, Gaur S. Chemically modified tetracyclines: novel therapeutic agents in the management of chronic periodontitis. Indian J Pharmacol 2012; 44 : 161-7. Ann Periodontol Reddy MS 8 12 2003 Reddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with antiproteinase. anti-inflammaory.and bone-sparing agents a systematic review. Ann Periodontol 2003; 8 : 12-37. J Periodontol Preshaw PM 79 440 2008 Preshaw PM, Novak MJ, Mellonig J. Modified release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol 2008; 79 : 440-52. J Periodontol Gapski R 75 441 2004 Gapski R, Barr JL, Sarment DP, Layher MG, Socransky SS, Giannobile WV. Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: a proof of concept trial. J Periodontol 2004; 75 : 441-52. J Dent Res Golub LM 89 644 2010 Golub LM, Lee HM, Stoner JA. Doxycycline effects on serum bone biomarkers in post-menopausal women. J Dent Res 2010; 89 : 644-9. J Clin Periodontol Reinhardt RA 34 768 2007 Reinhardt RA, Stoner JA, Golub LM. Efficacy of sub-antimicrobial dose doxycycline in post-menopausal women: clinical outcomes. J Clin Periodontol 2007; 34 : 768-5. J Periodontol Golub LM 79 1409 2008 Golub LM, Lee HM, Stoner JA. Subantimicrobial dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women. J Periodontol 2008; 79 : 1409-8. J Am Dent Assoc Payne JB 142 262 2011 Payne JB, Golub LM, Stoner JA. The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation. J Am Dent Assoc 2011; 142 : 262-73. Am J Vet Res Kim SE 74 130 2013 Kim SE, Kim S, Jeong M. Experimental determination of a sub antimicrobial dosage of doxycycline hyclate for treatment of periodontitis in Beagles. Am J Vet Res 2013; 74 : 130-5. J Periodontol Sgolastra F 82 1570 2011 Sgolastra F, Petrucci A, Gatto R, Giannoni M, Monaco A. Long-term efficacy of subantimicrobial-dose doxycycline as an adjunctive treatment to scaling and root planing: a sys-tematic review and meta-analysis. J Periodontol 2011; 82 : 1570-81. Pharmacol Res Monk E 63 130 2011 Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res 2011; 63 : 130-45. J Am Acad Dermatol Sapadin AN 54 258 2006 Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54 : 258-65. Ann NY Acad Sci Ryan ME 878 311 1999 Ryan ME, Ramamurthy NS, Sorsa T, Golub LM. MMP mediated events in diabetes. Ann NY Acad Sci 1999; 878 : 311-4. Pharmacol Res Garrido-Mesa N 63 308 2011 Garrido-Mesa N, Camuesco D, Arribas B et?al. The intestinal anti-inflammatory effect of minocycline in experimental colitis involves both its immunomodulatory and antimicrobial properties. Pharmacol Res 2011; 63 : 308-19. Pharmacol Rep Cai Z 63 381 2011 Cai Z, Zhao Y, Yao S, Bin Zhao B. Increases in ß-amyloid protein in the hippocampus caused by diabetic metabolic disorder are blocked by minocycline through inhibition of NF-?B pathway activation. Pharmacol Rep 2011; 63 : 381-91. J Am Coll Cardiol Scarabelli TM 43 865 2004 Scarabelli TM, Stephanou A, Pasini E et?al. Minocycline inhibits caspase activation and reactivation. increases the ratio of XIAP to smac/DIBLO.and reduces the mitochon-drial leakage of cytochrome C and smac/DIABLO. J Am Coll Cardiol 2004; 43 : 865-74. Pharmacol Res Bench TJ 64 561 2011 Bench TJ, Jeremias A, Brown DL. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease. Pharmacol Res 2011; 64 : 561-6. Proc Natl Acad Sci USA Alano CC 103 9685 2006 Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 2006; 103 : 9685-0. J Neurochem Nikodemova M 96 314 2006 Nikodemova M, Duncan ID, Watters JJ. Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and I?Ba degradation in a stimulus-specific manner in microglia. J Neurochem 2006; 96 : 314-23. J Neuroinflamm Henry CJ 5 15 2008 Henry CJ, Huang Y, Wynne A et?al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation. sickness behaior.and anhedonia. J Neuroinflamm 2008; 5 : 15. Korean J Physiol Pharmacol Park CH 15 115 2011 Park CH, Shin TK, Lee HY, Kim SJ, Lee WS. Matrix metalloproteinase inhibitors attenuate neuroinflammation following focal cerebral ischemia in mice. Korean J Physiol Pharmacol 2011; 15 : 115-22. Brain Behav Immun Markovic DS 25 624 2011 Markovic DS, Vinnakota K, van Rooijen N et?al. Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression. Brain Behav Immun 2011; 25 : 624-8. Autophagy Liu WT 7 166 2011 Liu WT, Lin CH, Hsiao M, Gean PW. Minocycline inhibits the growth of glioma by inducing autophagy. Autophagy 2011; 7 : 166-75. Toxicol Appl Pharmacol Huang TY 237 69 2009 Huang TY, Chu HC, Lin YL et?al. Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. Toxicol Appl Pharmacol 2009; 237 : 69-82. Inflamm Bowel Dis Perencevich M 12 651 2006 Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006; 12 : 651-4. Inflamm Bowel Dis Schultz M 14 1012 2008 Schultz M. Clinical use of E.coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14 : 1012-8. Biochem Pharmacol Garrido-Mesa N 82 1891 2011 Garrido-Mesa N, Utrilla P, Comalada M et?al. The association of minocycline and the probiotic Escherichia coli Nissle 1917 results in an additive beneficial effect in a DSS model of reactivated colitis in mice. Biochem Pharmacol 2011; 82 : 1891-900. Lancet Neurol Yong VW 3 744 2004 Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004; 3 : 744-51. Neuroscientist Stirling DP 11 308 2005 Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist 2005; 11 : 308-22. Am J Physiol Renal Physiol Sutton TA 288 F91 2005 Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 2005; 288 : F91-7. Curr Drug Deliv Jordan J 4 225 2007 Jordan J, Fernandez-Gomez FJ, Ramos M, Ikuta I, Aguirre N, Galindo MF. Minocycline and cytoprotection: shedding new light on a shadowy controversy. Curr Drug Deliv 2007; 4 : 225-31. Neurol Lampl Y 69 1404 2007 Lampl Y, Boaz M, Gilad R. Minocycline treatment in acute stroke: an open-label. evaluator-blinded study. Neurol 2007; 69 : 1404-0. Circulation Andrassy M 117 3216 2008 Andrassy M, Volz HC, Igwe JC et?al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008; 117 : 3216-26. Eur J Pharmacol. Hu X 638 84 2010 Hu X, Zhou X, He Betal. Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Eur J Pharmacol 2010; 638 : 84-9. J Cardiovasc Pharmacol. Tao R 56 659 2010 Tao R, Kim SH, Honbo N, Karliner JS, Alano CC. Minocycline protects cardiac myocytes against simulated ischemia reperfusion injury by inhibiting poly (ADP-ribose) polymerase-1. J Cardiovasc Pharmacol 2010; 56 : 659-8. Atherosclerosis. Shahzad K 219 74 2011 Shahzad K, Thati M, Wang Hetal. Minocycline reduces plaque size in diet induced atherosclerosis via p27(Kip1). Atherosclerosis 2011; 219 : 74-83. Pharmacol Res. Gu Y 64 573 2011 Gu Y, Lee HM, Sorsa T. Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease a mechanistic link between local and systemic inflammation. Pharmacol Res 2011; 64 : 573-9. Scand J Immunol. Alfakry H 76 181 2012 Alfakry H, Sinisalo J, Paju S. The association of serum neutrophil markers and acute coronary syndrome. Scand J Immunol 2012; 76 : 181-7. Pharmacol Res. Sorsa T 63 108 2011 Sorsa T, Tervahartiala T, Leppilahti J. Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol Res 2011; 63 : 108-3. Preshaw PM, Ed. Warnakulasuriya S and Tilakaratne WM. In Oral Medicine & Pathology a guide to diagnosis and management Chapter 3: Periodontal disease . 1st ed.. Publishers New Delhi.: Jaypee Brothers Medical 2014; pp. 50-81. Nutr Metab Marchetti E 9 88 2012 Marchetti E, Monaco A, Procaccini L. Periodontal disease: the influence of metabolic syndrome. Nutr Metab 2012; 9 : 88. Eur J Epidemiol Merchant AT 18 891 2003 Merchant AT, Pitiphat W, Rimm EB, Joshipura K. Increased physical activity decreases periodontitis risk in men. Eur J Epidemiol 2003; 18 : 891-. Bone Alikhani M 40 345 2007 Alikhani M, Alikhani Z, Boyd C. Advanced glycation end products stimulate osteoblast apoptosis via MAP kinase and cytosolic apoptotic pathways. Bone 2007; 40 : 345-53. Mediators Inflamm Borges I Jr 4 57 2007 Borges I Jr, Moreira EA, Filho DW, de Oliveira TB, da Silva MB, Frode TS. Pro-inflammatory and oxidative stress markers in patients with periodontal disease. Mediators Inflamm 2007; 4 : 57-94. J Clin Periodontol Montebugnoli L 31 25 2004 Montebugnoli L, Servidio D, Miaton RA, Prati C, Tricoci P, Melloni C. Poor oral health is associated with coronary heart disease and elevated systemic inflammatory and haemostatic factors. J Clin Periodontol 2004; 31 : 25-9. J Periodontol Al-Zahrani MS 76 1362 2005 Al-Zahrani MS, Borawski EA, Bissada NF. Periodontitis and three health-enhancing behaviours: maintaining normal weight. engaging in recommended level of exercise and consuming a high quality diet. J Periodontol 2005; 76 : 1362-6. Obes Res Pischon T 11 1055 2003 Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Rim EB. Leisure time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obes Res 2003; 11 : 1055-64. J Clin Endocrinol Metab Hansel B 89 4963 2004 Hansel B, Giral P, Nobecourt E. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004; 89 : 4963-71. Arterioscler Thromb Vasc Biol Koyama H 25 2587 2005 Koyama H, Shoji T, Yokoyama M. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25 : 2587-93. Cardiovasc Res Basta G 63 582 2004 Basta G, Schmidt AM, Decaterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63 : 582-92. Pharmacol Res Castro MM 64 551 2011 Castro MM, Kandasamy AD, Youssef N, Schulz R. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular disease. Pharmacol Res 2011; 64 : 551-60. Arterioscler Thromb Vasc Biol Brown DL 24 733 2004 Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004; 24 : 733-8. N Engl J Med Ridker PM 359 2195 2008 Ridker PM, Danielson E, Fonseca FA. Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein. N Engl J Med 2008; 359 : 2195-07. Inflamm Res Salminen A 62 711 2013 Salminen A, Pussinen PJ, Payne JB. Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages. Inflamm Res 2013; 62 : 711-20. Stroke Axisa B 33 2858 2002 Axisa B, Loftus IM, Naylor AR. Prospective. randomzed.double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 2002; 33 : 2858-64. Am J Pathol Bendeck MP 160 1089 2002 Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM. Doxycycline modulates smooth muscle cell growth. migraion.and matrix remodelling after arterial le-sions. Am J Pathol 2002; 160 : 1089-95. J Vasc Surg Baxter BT 36 1 2002 Baxter BT, Pearce WH, Waltke EA. Prolonged administration of doxycycline in patients with small asymptomatic aortic aneurysms: report of a prospective (Phase II) multi-centre study. J Vasc Surg 2002; 36 : 1-12. JAMA Ludvig DS 287 2414 2002 Ludvig DS. The glycemic index physiological mechanisms relating to obesity. diabetes and cardiovascular disease. JAMA 2002; 287 : 2414-3. Oral Sur Oral Med Oral Pathol Oral Radiol Endocrinol Janket SJ 105 173 2008 Janket SJ, Jones JA, Meurman JH, Baird AE, Van Dyke TE. Oral Infection. hyperglycemia and endothelial dysfunction. Oral Sur Oral Med Oral Pathol Oral Radiol Endocrinol 2008; 105 : 173-9. Open Diabetes J Nakao C 2 53 2009 Nakao C, Angel M, Di Mateo S, Komesu MC. Effects of topical tetracycline in wound healing on experimental diabetes in rats. Open Diabetes J 2009; 2 : 53-9. J Periodontol Mustapha IZ 78 2289 2007 Mustapha IZ, Debrey S, Oladubu M, Ugarte R. Markers of systemic bacterial exposure in periodontal disease and cardiovascular disease risk: a systematic review and meta-analysis. J Periodontol 2007; 78 : 2289-02. Atheroscler Thromb Vasc Biol Grundy SM 25 2243 2005 Grundy SM. Metabolic syndrome scientific statement by the American Heart Association and the National Heart.Lung and Blood Institute. Atheroscler Thromb Vasc Biol 2005; 25 : 2243-4. J Periodontol Fukui N 83 1363 2012 Fukui N, Shimazaki Y, Shinagawa T, Yamashita Y. Periodontal status and metabolic syndrome in middle-aged Japanese. J Periodontol 2012; 83 : 1363-71. J Clin Periodontol Kwon YE 38 781 2011 Kwon YE, Ha JE, Paik DI, Jin BH, Bae KH. The relationship between periodontitis and metabolic syndrome among a Korean nationally representative sample of adults. J Clin Periodontol 2011; 38 : 781-6. J Periodontol Kushiyama M 80 1610 2009 Kushiyama M, Shimazaki Y, Yamashita Y. Relationship between metabolic syndrome and periodontal disease in Japanese adults. J Periodontol 2009; 80 : 1610-5. J Clin Endocrinol Metab D’Aiuto F 93 3989 2008 D’Aiuto F, Sabbah W, Netuveli G . Association of nthe metabolic syndrome with severe periodontitis in a large US population-based survey. J Clin Endocrinol Metab 2008; 93 : 3989-94. Obesity Reviews Suvan J 12 e404 2011 Suvan J, D’Aiuto F, Moles DR, Petrie A, Donos N. Association between overweight/obesity and periodontitis in adults: a systematic review. Obesity Reviews 2011; 12 : e404-81. J Periodontol Chaffee BW 81 1708 2010 Chaffee BW, Weston SJ. Association between chronic periodontal disease and obesity: a systematic review and meta-analysis. J Periodontol 2010; 81 : 1708-24. J Clin Periodontol Gorman A 39 107 2012 Gorman A, Kaye EK, Apovian C, Fung TT, Nunn M, Garcia RI. Overweight and obesity predict time to periodontal periodontal disease progression in men. J Clin Periodontol 2012; 39 : 107-4. J Diabetes Complicat Hirsh IB 19 178 2005 Hirsh IB, Brownlee M. Should minimum blood glucose variability become the gold standard of glycemic control?. J Diabetes Complicat 2005; 19 : 178-81. Diabetologia Preshaw PM 55 21 2012 Preshaw PM, Alba AL, Herrera D. Periodontisis and diabetes: a two-way relationship. Diabetologia 2012; 55 : 21-31. Circulation Esposito K 106 2067 2002 Esposito K, Nappo F, Marfella R. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106 : 2067-72. Endocr Metab Immune Disord Drug Targets Rahman ZA 6 279 2006 Rahman ZA, Soory M. Antioxidant effects of glutathione and IGF in a hyperglycaemic cell culture model of fibroblasts: some actions of advanced glycaemic end products (AGE) and nicotine. Endocr Metab Immune Disord Drug Targets 2006; 6 : 279-86. Recent Pat Endocr Metab Immune Drug Discov Tilakaratne A 6 73 2012 Tilakaratne A, Soory M. Osteoblastic responses to LPS. glucose oxidized LDL and minocycline: therapeutic targets for periodontal and cardiometabolic diseases. Recent Pat Endocr Metab Immune Drug Discov 2012; 6 : 73-84. Ann Periodontol Grossi SG 3 51 1998 Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: a two-way relationship. Ann Periodontol 1998; 3 : 51-61. Soory M, El-Shinnawi U, Veas F, Eds. In: Acute phase proteins as early non-specific biomarkers of human and veterinary diseases.Chapter 3: Diagnostic value of acute phase proteins in periodotal.psychosomatic and cardiometabolic diseases response to treatment. In Tech. 2011; pp. 43-68. Pharmacol Res Engebretson SP 64 624 2011 Engebretson SP, Hey-Hadavi J. Sub-antimicrobial doxycycline for periodontitis reduces hemoglobin A1c in subjects with type 2 diabetes: a pilot study. Pharmacol Res 2011; 64 : 624-9. J Periodontol Emingil G 82 452 2011 Emingil G, Gurkan A, Atilla G, Kantarci A. Sub-antimicrobialdose doxycycline and cytokine-chemokine levels in gingival crevicular fluid. J Periodontol 2011; 82 : 452-61. J Periodontol Javed F 83 156 2012 Javed F, Al-Askar M, Al-Hezaimi K. Cytokine profile in the gingival crevicular fluid of periodontitis patients with and without type 2 diabetes: a literature review. J Periodontol 2012; 83 : 156-61. J Int Acad Periodontol Fell RA 15 20 2013 Fell RA, Zeek Y, Arora M. The correlation of serum and gingival crevicular fluid cytokines in obese subjects. J Int Acad Periodontol 2013; 15 : 20-8. Pharmacol Res Federici TJ 64 614 2011 Federici TJ. The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease. Pharmacol Res 2011; 64 : 614-23. Med Gen Med Ogrendik M 7 2 2005 Ogrendik M, Kokino S, Ozdemir F, Bird PS, Hamlet S. Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis. Med Gen Med 2005; 7 : 2-10. Arthritis Rheum Lundberg K 58 3009 2008 Lundberg K, Kinloch A, Fisher BA. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008; 58 : 3009-19. Arthritis Rheum Wegner N 62 2662 2010 Wegner N, Wait R, Sroka A. Peptidylarginine deiminase from porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: Implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010; 62 : 2662-72. J Periodontol Ortiz P 80 535 2009 Ortiz P, Bissada NF, Palomo L. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumour necrosis factor inhibitors. J Periodontol 2009; 80 : 535-40. J Periodontol Havemose-Poulsen A 76 2276 2005 Havemose-Poulsen A, Serensen LK, Stoltze K, Bendtzen K, Holmstrup P. Cytokine profiles in peripheral blood and whole blood cell cultures associated with aggressive periodontitis. juvenile idiopathic arthritis and rheumatoid arthritis. J Periodontol 2005; 76 : 2276-85. Ann Rheum Dis Marrotte H 65 905 2006 Marrotte H, Farge P, Gaudin P, Alexandre C, Mougin B, Moussec P. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitopes. Ann Rheum Dis 2006; 65 : 905-. J Clin Periodontol Bartold PM 37 405 2010 Bartold PM, Marino V, Cantley M, Haynes DR. Effect of Porphyromonas gingivalis-induced inflammation on the development of rheumatoid arthritis. J Clin Periodontol 2010; 37 : 405-11. Autoimmun Rev Ospelt C 10 519 2011 Ospelt C, Reedquist KA, Gay S, Tak PP. Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis?. Autoimmun Rev 2011; 10 : 519-24. J Oral Microbiol Persson GR 4 11829 2012 Persson GR. Rheumatoid arthritis and periodontitis - inflammatory and infectious connections: review of the literature. J Oral Microbiol 2012; 4 : 11829. J Rheumatol Stone M 30 2112 2003 Stone M, Fortin PR, Pacheco-Tena C, Inman RD. Should tetracycline treatment be used more extensively for rheumatoid arthritis?.Meta-analysis demonstrates clinical benefit with reduction in disease activity. J Rheumatol 2003; 30 : 2112-2. Pharmacol Res Greenwald RA 64 610 2011 Greenwald RA. The road forward: the scientific basis for tetracycline treatment of arthritic disorders. Pharmacol Res 2011; 64 : 610-3. J Periodont Res Suzuki A 41 124 2006 Suzuki A, Yagisawa J, Kumakura S, Tsutsui T. Effects of minocycline and doxycycline on cell survival and gene expression in human gingival and periodontal ligament cells. J Periodont Res 2006; 41 : 124-31. Bone Holmes SG 35 471 2004 Holmes SG, Still K, Buttle DJ, Bishop NJ, Grabowski PS. Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors. Bone 2004; 35 : 471-8. Int Immunopharmacol D’Agostino P 1 1765 2001 D’Agostino P, Ferlazzo V, Milano S. Anti-inflammatory effects of chemically modified tetracyclines by the inhibition of nitric oxide and interleukin-12 synthesis in J774 cell line. Int Immunopharmacol 2001; 1 : 1765-76. Drug Saf Langevitz P 22 405 2000 Langevitz P, Livneh A, Bank I, Pras M. Benefits and risks of minocycline in rheumatoid arthritis. Drug Saf 2000; 22 : 405-14. J Mol Biol Dalm D 398 83 2010 Dalm D, Palm GJ, Aleksandrov A, Simonson T, Hinrichs W. Non-antibiotic properties of tetracyclines: struc-tural basis for inhibition of secretory phospholipase A2. J Mol Biol 2010; 398 : 83-96. Proteomics Dunston CR 11 42 2011 Dunston CR, Griffiths HR, Lambert PA, Staddon S, Vernallis AB. Proteomic analysis of the anti-inflammatory action of minocycline. Proteomics 2011; 11 : 42-51. FEBS J Gialeli C 278 16 2011 Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278 : 16-27. J Immunol Kinugawa S 188 1772 2012 Kinugawa S, Koide M, Kobayashi Y. Tetracyclines convert the osteoclastic-differentiation pathway of progenitor cells to produce dendritic cell-like cells. J Immunol 2012; 188 : 1772-81. Cochrane Database Syst Rev Nov1 da Costa BR CD007323 2012 da Costa BR, Nüesch E, Reichenbach S, Jüni P, Rutjes AW. Doxycycline for osteoarthritis of the knee or hip. Cochrane Database Syst Rev Nov1 2012; (11): CD007323. Indian J Dent Res Modi DK 20 86 2009 Modi DK, Chopra VS, Bhau U. Rheumatoid arthritis and periodontitis: Biological links and the emergence of dual purpose therapies. Indian J Dent Res 2009; 20 : 86-90. Eur J Pharmacol Gunella G 6 199 2006 Gunella G, Bardelli C, Spina S, Fresu LG, Viano I, Brunelleschi S. Anti-inflammatory drugs and tumour necrosis factor alpha production from monocytes: role of transcription factor NF- Kappa B and implications for rheumatoid arthritis therapy. Eur J Pharmacol 2006; 6 : 199-208. J Periodontol Lee HM 75 453 2004 Lee HM, Ciancio SG, Tüter G, Ryan ME, Komaroff E, Golub LM. Sub-antimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J Periodontol 2004; 75 : 453-63. Periodontol 2000 Noguchi K 43 85 2007 Noguchi K, Ishikawa I. The roles of cyclooxygenase-2 and prostaglandin E2 in periodontal disease. Periodontol 2000 2007; 43 : 85-101. FASEB J Kats A 27 2328 2013 Kats A, Båge T, Georgsson P. Inhibition of microsomal prostaglandin E synthase-1 by aminothiazoles decreases prostaglandin E2 synthesis in vitro and ameliorates experi-mental periodontitis in vivo. FASEB J 2013; 27 : 2328-41. J Periodontol Tilakaratne A 73 585 2002 Tilakaratne A, Soory M. The modulation of androgen metabolism by oestradiol. minocycline and indomethacin in a cell culture model. J Periodontol 2002; 73 : 585-90. J Clin Periodontol Soory M 30 1069 2003 Soory M, Tilakaratne A. Androgen metabolic response to indomethacin and the alkaline phosphatase inhibitor levamisole in fibroblasts. J Clin Periodontol 2003; 30 : 1069-74. Arch Pharm Res Yang JH 30 871 2007 Yang JH, Yun MY, Kim DK. Preparation and evaluation of ketorolac tromethamine gel containing genipin for periodontal diseases. Arch Pharm Res 2007; 30 : 871-5. J Lipid Res Rahman MM 47 1739 2006 Rahman MM, Bhattacharya A, Fernandes G. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264. cells by modulating RANKL signalling. J Lipid Res 2006; 47 : 1739-48. Joint Bone Spine Breuil V 73 349 2006 Breuil V, Euller-Ziegler L. Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 2006; 73 : 349-54. Arthritis Rheum Jarrett SJ 54 1410 2006 Jarrett SJ, Conaghan PG, Sloan VS. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 2006; 54 : 1410-4. Arthritis Res Ther Calmon-Hamaty F 13 232 2011 Calmon-Hamaty F, Combe B, Hahne M, Morel J. Lymphotoxin a revisited: general features and implications in rheumatoid arthritis. Arthritis Res Ther 2011; 13 : 232. J Periodontol Lane N 76 1113 2005 Lane N, Armitage GC, Loomer P. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month randomized placebo controlled study. J Periodontol 2005; 76 : 1113-22. J Periodontol Kamma JJ 71 1862 2000 Kamma JJ, Nakou M, Mitsis FJ. The clinical and microbiological effects of systemic ornidazole in sites with and without subgingival debridement in early-onset periodontitis patients. J Periodontol 2000; 71 : 1862-73. Rheumatology (Oxford) Ogrendik M 45 636 2006 Ogrendik M, Hakguder A, Keser N. Treatment of rheumatoid arthritis with ornidazole: a randomized double-blind placebo-controlled study. Rheumatology (Oxford) 2006; 45 : 636-7.